RTX vs SPRO · P/E 36, rev $88.60B vs P/E 9.6, rev $48.0M
RTX Corporation (RTX) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
RTX currently screens at market cap $259.34B and trailing P/E 36.2. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the RTX and SPRO stock pages for the full models.
Not investment advice.